Table6_A Novel Gene Signature Associated With “E2F Target” Pathway for Predicting the Prognosis of Prostate Cancer.XLS

Background: The effect of the adenoviral early region 2 binding factors (E2Fs) target pathway on prostate cancer is not clear. It is necessary to establish an E2F target-related gene signature to predict prognosis and facilitate clinical decision-making.
Methods: An E2F target-related gene signature was established by univariate and LASSO Cox regression analyses, and its predictive ability was verified in multiple cohorts. Moreover, the enrichment pathway, immune microenvironment, and drug sensitivity of the activated E2F target pathway were also explored.
Results: The E2F target-related gene signature consisted of MXD3, PLK1, EPHA10, and KIF4A. The patients with high-risk scores showed poor prognosis, therapeutic resistance, and immunosuppression, along with abnormal growth characteristics of cells. Tinib drugs showed high sensitivity to the expression of MXD3 and EPHA10 genes.
Conclusion: Our research established an E2F target-related signature for predicting the prognosis of prostate cancer. This study provides insights into formulating individualized detection and treatment as well as provides a theoretical basis for future research.

背景：腺病毒早期区域2结合因子（E2Fs）靶通路对前列腺癌的作用尚不明确，亟需构建E2F靶基因相关基因特征以预测患者预后、辅助临床决策。
方法：本研究通过单因素及LASSO Cox回归分析构建了E2F靶基因相关基因特征，并在多队列中验证其预测效能。此外，本研究还探讨了激活的E2F靶通路的富集通路、免疫微环境及药物敏感性。
结果：该E2F靶基因相关基因特征由MXD3、PLK1、EPHA10及KIF4A四个基因组成。高危评分患者预后较差，存在治疗耐药与免疫抑制状态，同时伴随细胞生长特性异常。Tinib药物对MXD3与EPHA10基因的表达具有较高敏感性。
结论：本研究构建了可用于预测前列腺癌患者预后的E2F靶基因相关特征模型。本研究为制定个体化检测与治疗方案提供了思路，同时也为未来的相关研究奠定了理论基础。